WO2001030964A3 - Anti-cancer nucleic acid and protein targets - Google Patents

Anti-cancer nucleic acid and protein targets Download PDF

Info

Publication number
WO2001030964A3
WO2001030964A3 PCT/US2000/029126 US0029126W WO0130964A3 WO 2001030964 A3 WO2001030964 A3 WO 2001030964A3 US 0029126 W US0029126 W US 0029126W WO 0130964 A3 WO0130964 A3 WO 0130964A3
Authority
WO
WIPO (PCT)
Prior art keywords
nucleic acid
protein targets
cancer nucleic
cancer
neoplasia
Prior art date
Application number
PCT/US2000/029126
Other languages
French (fr)
Other versions
WO2001030964A2 (en
Inventor
Glenna C Burmer
Joseph P Brown
David Pritchard
Original Assignee
Lifespan Biosciences Inc
Glenna C Burmer
Joseph P Brown
David Pritchard
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lifespan Biosciences Inc, Glenna C Burmer, Joseph P Brown, David Pritchard filed Critical Lifespan Biosciences Inc
Priority to AU13397/01A priority Critical patent/AU1339701A/en
Publication of WO2001030964A2 publication Critical patent/WO2001030964A2/en
Publication of WO2001030964A3 publication Critical patent/WO2001030964A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds

Abstract

This invention relates to the discovery of nucleic acids associated with cell proliferation, neoplasia, cell transformation, malignant tumor formation and metastasis and uses therefor.
PCT/US2000/029126 1999-10-22 2000-10-20 Anti-cancer nucleic acid and protein targets WO2001030964A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU13397/01A AU1339701A (en) 1999-10-22 2000-10-20 Anti-cancer nucleic acid and protein targets

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US16123299P 1999-10-22 1999-10-22
US60/161,232 1999-10-22
US69378300A 2000-10-19 2000-10-19
US09/693,783 2000-10-19

Publications (2)

Publication Number Publication Date
WO2001030964A2 WO2001030964A2 (en) 2001-05-03
WO2001030964A3 true WO2001030964A3 (en) 2001-08-09

Family

ID=26857637

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/029126 WO2001030964A2 (en) 1999-10-22 2000-10-20 Anti-cancer nucleic acid and protein targets

Country Status (2)

Country Link
AU (1) AU1339701A (en)
WO (1) WO2001030964A2 (en)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7867731B2 (en) 1998-11-04 2011-01-11 Novartis Vaccines And Diagnostics, Inc. HX2004-6 polypeptide expressed in cancerous cells
US20030045491A1 (en) 2001-02-23 2003-03-06 Christoph Reinhard TTK in diagnosis and as a therapeutic target in cancer
AU2002215689B2 (en) * 2000-12-11 2006-05-18 Biosceptre Pty Ltd P2Y purinergic receptor expression for identifying preneoplastic and neoplastic states
AUPR201500A0 (en) * 2000-12-11 2001-01-11 Biosceptre Pty Ltd Methods for identifying pre-neoplastic and neoplastic states in mammals
ES2383712T3 (en) 2001-01-17 2012-06-25 Biosceptre International Limited Diagnosis and treatment of cancers and other conditions
AU2002239800A1 (en) * 2001-02-01 2002-08-12 Lifespan Biosciences, Inc. Gpr22, a g protein-coupled receptor (gpcr) and compositions and methods related thereto
US7501243B2 (en) 2001-02-21 2009-03-10 Novartis Vaccines And Diagnostics, Inc. Detection of colon or breast cancer by measuring TTK polypeptide expression
AU2007203399B2 (en) * 2001-02-21 2009-12-03 Novartis Vaccines And Diagnostics, Inc. TTK in diagnosis and as a therapeutic target in cancer
KR100876327B1 (en) * 2001-02-21 2008-12-31 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 TV as a therapeutic target in diagnosis and in cancer
DE60237917D1 (en) * 2001-06-05 2010-11-18 Exelixis Inc GFATS AS MODULATORS OF THE P53 PATH AND METHOD OF USE
EP1412754A4 (en) * 2001-06-27 2005-10-19 Inst Medical W & E Hall Diagnostic methods and agents
NZ571508A (en) 2002-05-24 2010-05-28 Schering Corp Neutralizing human anti-IGFR antibody
EP1382969A1 (en) * 2002-07-17 2004-01-21 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Diagnosis and prevention of cancer cell invasion
CN1938428A (en) 2003-11-12 2007-03-28 先灵公司 Plasmid system for multigene expression
AR046639A1 (en) 2003-11-21 2005-12-14 Schering Corp ANTI-IGFR1 ANTIBODY THERAPEUTIC COMBINATIONS
US8415315B2 (en) * 2004-05-06 2013-04-09 University Of Central Florida Research Foundation, Inc. Methods and compositions for inhibiting the proliferation of cancer cells
ATE493442T1 (en) 2004-12-03 2011-01-15 Schering Corp BIOLOGICAL MARKERS FOR PRE-SELECTION OF PATIENTS FOR ANTI-IGF1R THERAPY
EP1910569A4 (en) * 2005-06-17 2009-08-05 Genizon Biosciences Inc Genemap of the human genes associated with longevity
WO2008043145A1 (en) 2006-10-10 2008-04-17 Biosceptre International Limited Hybridomas producing antibodies against non functional p2x7 receptor
WO2009033233A1 (en) 2007-09-14 2009-03-19 Biosceptre International Limited Novel p2x7 epitopes
US8293491B2 (en) 2007-09-14 2012-10-23 Biosceptre International Limited Purinergic (P2X) receptors in extra-cellular body fluid
NZ590146A (en) 2008-07-04 2012-09-28 Biosceptre Int Ltd Antibodies which bind an epitope comprising two different monomers of the P2X7 receptor
ES2557456T3 (en) 2009-08-20 2016-01-26 Biosceptre (Aust) Pty Ltd P2X7 anti-receptor antibodies and fragments thereof
AU2010336032C1 (en) 2009-12-24 2016-04-21 Biosceptre International Limited Antibodies to non-functional oligomeric P2X7 receptors
EP2613808B1 (en) 2010-09-10 2017-11-08 Biosceptre (Aust) Pty Ltd Companion animal cancer treatments with an anti p2x7 antibody
JP6305920B2 (en) 2011-07-01 2018-04-04 バイオセプター・（オーストラリア）・ピーティーワイ・リミテッド Combination therapy

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE GENBANK [online] NATIONAL CENTER FOR BIOTECHNOLOGY INFORMATION, NATIONAL LIBRARY OF MEDICINE, BETHESDA, MD; 19 December 1996 (1996-12-19), SCHIMMOELLER ET AL.: "P76 is a human member of an emerging family of multispanning membrane proteins", XP002939553, Database accession no. U81006 *

Also Published As

Publication number Publication date
AU1339701A (en) 2001-05-08
WO2001030964A2 (en) 2001-05-03

Similar Documents

Publication Publication Date Title
WO2001030964A3 (en) Anti-cancer nucleic acid and protein targets
WO1999057325A3 (en) Enzymes mixture
AU4903101A (en) Isolated nucleic acid molecules encoding cancer associated antigens, the antigens per se, and uses thereof
WO2001002568A3 (en) Human genes and gene expression products
AU3246300A (en) Polypeptides having galactose oxidase activity and nucleic acids encoding same
WO2000028090A3 (en) Diagnostic assay for cancer
EP1325932A3 (en) Anti-vegf antibodies
WO2000060060A3 (en) Polypeptides having alkaline alpha-amylase activity and nucleic acids encoding same
WO1999035170A8 (en) Compositions and methods for the treatment of tumor
WO2001053312A8 (en) Novel nucleic acids and polypeptides
WO2001053455A3 (en) Novel nucleic acids and polypeptides
WO2000060058A3 (en) Polypeptides having alkaline alpha-amylase activity and nucleic acids encoding same
AU2001242299A1 (en) Fungal transcriptional activator useful in methods for producing polypeptides
WO2001029222A3 (en) Polypeptides having phospholipase b activity and nucleic acids encoding same
WO2000053755A3 (en) Compositions and methods for the treatment of tumor
WO2001025273A3 (en) Compositions and methods for wt1 specific immunotherapy
WO2002006457A3 (en) Novel lipase genes
WO2005047459A3 (en) Sars nucleic acids, proteins, antibodies, and uses thereof
PL336983A1 (en) Compounds, their production and application as carriers of nucleic acids in cells
WO2000075317A3 (en) Compositions and methods for the treatment of tumor
WO2002064839A3 (en) Methods for the diagnosis and treatment of tumors employing the hepsin gene
AU5850999A (en) Fungal transcriptional activator useful in methods for producing polypeptides
AU2658200A (en) Oxaloacetate hydrolase deficient fungal host cells
WO2001032935A3 (en) Molecular microarrays and methods for production and use thereof
WO2003044161A3 (en) Gene amplification and overexpression in cancer

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase